VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that its largest shareholder, AlphaNorth Asset Management (“AlphaNorth”), has increased its ownership position in the Company by acquiring 150,000 shares in the recent private placement financing. As a result…


Previous articleGH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
Next articleClearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment